As the world becomes more interconnected through globalization & urbanization the risk of future epidemics and pandemics is steadily increasing. The emergence of antibiotic-resistant bacteria further compounds the problem. Consequently, there is a growing demand for products that can effectively halt the spread of viruses and bacteria.
FNDX Technologies Inc. (FNDX.C) with its unique use of proprietary nanotechnology, is developing cutting-edge solutions that can prevent the transmission of pathogens. Its flagship product, REPELWRAP™ film, is a surface coating that repels bacteria and viruses, reducing the risk of infection.
Unlike traditional pathogen-killing products that may lead to antibiotic resistance, REPELWRAP™ uses nanotechnology to repel pathogens without killing them. This innovative product can be easily applied to a variety of surfaces, making it a valuable tool for infection control.
With plans to launch in Canada in 2024, FNDX is well-positioned to meet the rising demand for pathogen-preventing products.
Another thing that poises FNDX for success is its accomplished management team that has extensive experience in healthcare and corporate finance. CEO Dr. Carolyn Myers has a wealth of experience in creating, growing, and leading healthcare businesses. In addition to her role at FendX, she is a Principal at BioEnsemble LLC, where she works closely with start-ups and small pharma companies to develop business strategies.
Andrea Mulder, the COO of FendX, brings extensive sales and marketing experience from leading pharmaceutical and biotechnology corporations in Canada.
Finally, CFO Rose Zanic has significant experience advising Canadian public companies on financing, M&A transactions, and public company administration. Together, this management team provides FendX with a unique blend of expertise to support the growth and development of the company.
Check out FNDX's website for more information: https://fendxtech.com Posted on behalf of FendX Technologies Inc.